A comparison of lipid and lipoprotein measurements in the fasting and nonfasting states in patients with type 2 diabetes

Current Medical Research and Opinion

Volumn 23, Issue 11, 2007, Pages 2689-2695

  Dungan, Kathleen M ^a,c   Guster, Tia ^b   DeWalt, Darren A ^b   Buse, John B ^b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c McCampbell Hall ^*  (United States)

Author keywords

Cholesterol; Diabetes; LDL; NMR; Non HDL; Nonfasting

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS;

DIABETES MELLITUS, TYPE 2; FASTING; HUMANS; LIPIDS; LIPOPROTEINS;

EID: 36348983798     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X233304     Document Type: Article

References (35)

1. Goff DC Jr, D'Agostino RB Jr, Haffner SM, Otvos JD. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism 2005;54:264-70
2. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003;52:453-62
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high cholesterol in adults (Adult Treatment Panel III). Circulation 2002;106:3143-421
4. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 2007;30:S4-41
5. National Committee for Quality Assurance. P4P Measurement Year 2006 Clinical Specifications November Updates. Available at http://web.ncqa.org/ LinkClick.aspx?fileticket=DTP8daVLz7c%3D&tabid=212&mid= 1153&forcedownload=true. Accessed 3/30/07
6. Bottorff MB. Underidentification and undertreatment issues. J Manag Care Pharm 2003;9:6-8
7. Kristensen J, Lauritzen T. Inadequate treatment of dyslipidemia in people with type 2 diabetes: quality assessment of diabetes care in a Danish County. Scand J Prim Health Care 2006;24:181-5
8. Primatesta P, Pouter NR. Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003. Clin Endocrinol 2006;64:292-8
9. Wilder LB, Bachorik PS, Finney CA, et al. The effect of fasting status on the determination of low-density and high-density lipoprotein cholesterol. Am J Med 1995;99:374-7
10. Schaefer EJ, Audelin MC, McNamara JR, et al. Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease. Am J Cardiol 2001;88:1129-33
11. Weiss R, Harder M, Rowe J. The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Ther 2003;25:1490-7
12. Bittner V. Non-high-density lipoprotein cholesterol: an alternate target for lipid-lowering therapy. Prev Cardiol 2004;7:122-6
13. Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-1 and B100, standard lipid measures, lipid ratios and CRP as risk factors for cardiovascular disease in women. JAMA 2005;294:326-33
14. Jiang R, Schulze MB, Li T, et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 2004;27:1991-7
15. Wagner AM, Perez A, Zapico E, Ordonez-Llanos J. Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients. Diabetes Care 2003;26:2048-51
16. Liu J, Sempos C, Donahue R, et al. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care 2005;28:1916-21
17. Craig SR, Amin RV, Russell DW, Paradise NF. Blood cholesterol screening influence of fasting state on cholesterol results and management decisions. J Gen Intern Med 2000;15:395-9
18. Kuller L, Arnold A, Tracy R, Otvos, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 2002;22:1175-80
19. El Harchaoui K, van der Steeg WA, Stroes ES, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;49:547-53
20. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002;106:1930-7
21. Otvos JD, Collins D, Freedman DS, etal. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006;28;113:1556-63
22. Roeters van Lennep JE, Westerveld HT, van Roeters Lennep HWO, et al. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events, Arterioscler Thromb Vasc Biol 2000; 20:2408-13
23. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006;26:847-70
24. Rivellese AA, De Natale C, Di Marino L, et al. Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal triglyceride levels. J Clin Endocrin 2004;89:2153-9
25. Cohn JS, McNamara JR, Schaefer EJ. Lipoprotein cholesterol concentrations in the plasma of human subjects as measured in the fed and fasted states. Clin Chem 1988;34:2456-9
26. Ragland BD, Konrad RJ, Chaffin C, et al. Evaluation of a homogeneous direct LDL-cholesterol assay in diabetic patients: effect of glycemic control. Clin Chem 2000;46: 1848-51
27. Nauck M, Graziani MS, Bruton D, et al. Analytical and clinical performance of a detergent-based homogeneous LDL-cholesterol assay: a multicenter evaluation. Clin Chem 2000;46:506-14
28. Ambus T, Korogyi N, DeCampos F, et al. Evaluation of the Beckman Synchron CX4 clinical chemistry analyzer in a hospital laboratory. J Clin Lab Anal 1990; 4:120-5
29. Bairaktari E, Hatzidimou K, Tzallas C, et al. Estimation of LDL cholesterol based on the Friedewald formula and on apo B levels. Clin Biochem 2000;33:549-55
30. U.S. Department of Health and Social Services. Medicare, Medicaid, and CLIA Programs: Regulations implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Final Rule. Fed Regist 1992;57:7002-186
31. Mora S, Szklo M, Otvos JD, et al.. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007;192:211-17
32. Cromwell WC, Otvos JD. Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl. Am J Cardiol 2006;98:1599-602
33. Rosenthal MB, Landon BE, Normand SL, et al. Pay for performance in commercial HMOs. N Engl J Med. 2006;355:1895-902
34. Doran T, Fullwood C, Gravelle H, et al. Pay-for-performance programs in family practices in the United Kingdom. N Engl J Med 2006;355:375-84
35. CM. Bell and W. Levinson. Pay for performance: learning about quality. Can Med Assoc J 2007;176:1717-19